The association of weight gain and olanzapine plasma concentrations

Journal of Clinical Psychopharmacology

Volumn 25, Issue 3, 2005, Pages 250-254

  Perry, Paul J ^a,b,e   Argo, Tami R ^a   Carnahan, Ryan M ^a,c   Lund, Brian C ^d   Holman, Timothy L ^a,b   Ellingrod, Vicki L ^a   Miller, Del ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d Laureate Psychiatric Clinic and Hospital   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SIDE EFFECT; WEIGHT GAIN;

ADULT; BENZODIAZEPINES; CLINICAL TRIALS; CONFIDENCE INTERVALS; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 18844456619     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000162800.64378.82     Document Type: Article

References (24)

1. Henderson DC. Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents. Curr Diab Rep. 2002;2(2):135-140.
2. Allison DB, Mentore JL, Moonseon H, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
3. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in subjects with schizophrenia treated with olanzapine, haloperidol or risperidone. J Clin Psychiatry. 2001;62:231-238.
4. Frankenburg FR, Zanarini MC, Kando J, et al. Clozapine and body mass change. Biol Psychiatry. 1998;43:520-524.
5. Hummer M, Kemmler G, Kurz M, et al. Weight gain induced by clozapine. Eur Neuropsychopharmacol. 1995;5:437-440.
6. Jones B, Basson BR, Walker DJ, et al. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry. 2001;62(suppl 2):41-44.
7. Lane HY, Chang YC, Cheng YC, et al. Effects of subject demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry. 2003;64(3):316-320.
8. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res. 2002;29:19-27.
9. Perry PJ. Therapeutic drug monitoring of antipsychotics. Psychopharmacol Bull. 2001;35(3):19-29.
10. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14(2):111-123.
11. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154(4):457-465.
12. Ellingrod VL, Perry PJ, Lund BC, et al. 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J Clin Psychopharmacol. 2002;22(6):622-624.
13. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic subjects. J Clin Psychopharmacol. 1997;17:472-476.
14. Overall J, Gorham D. Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
15. Catlow JT, Barton RD, Clemens M, et al. Analysis of olanzapine in human plasma utilizing reversed-phase high performance liquid chromatography with electrochemical detection. J Chromatogr B. 1995;668:85-90.
16. SAS Institute. SAS/STAT Users Guide, Version 9.0. Cary, NC: SAS Institute Inc.; 2002.
17. Mossman D, Somoza E. ROC curves, test accuracy, and the description of diagnostic tests. J Neuropsychiatry Clin Neurosci. 1991;3(3):330-333.
18. Eli Lilly and Company. Zyprexa (olanzapine) package insert. Indianapolis, IN; March 29, 2004.
19. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry. 1997;58(suppl 10):45-49.
20. Braumwald E, Fauci AS, Kasper DL, eds., et al. Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw-Hill Professional; 2001.
21. Wetterling T, Mussigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol. 1999;19(4):316-321.
22. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention, National Institutes of Health, National Center for Health Statistics. National Health and Nutrition Examination Survey (NHANES) 1999-2000. Healthy weight, overweight, and obesity among persons 20 years of age and over, according to sex, age, race, and Hispanic origin: United States, 1960-62, 1971-74, 1976-80, 1988-94, and 1999-2000 [CDC website]. Available at: http://www.cdc.gov/nchs/data/hus/tables/2002/02hus070.pdf. Accessed December 4, 2003.
23. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62(2):92-100.
24. U.S. Department of Health and Human Services. Centers for Disease Control and Prevention, National Institutes of Health, National Center for Chronic Disease Prevention and Health Promotion. Nutrition and physical activity: BMI for adults [CDC website]. Available at: http://www.cdc.gov/nccdphp/dnpa/bmi/bmi- adult.htm. Accessed March 8, 2004.